Preoperative Systemic Inflammatory Indices as Predictors of Malignant Pathology in Repeat Transurethral Resection for High-risk Non-muscle Invasive Bladder Cancer: Insights from a Cross-Sectional Study

Creative Commons License

ATEŞ H. A., Yücetaş U., Okucu E., Miriyev T., Çakır M., Aracı M. H. E., ...Daha Fazla

Journal of Urological Surgery, cilt.12, sa.3, ss.181-188, 2025 (ESCI, Scopus, TRDizin)

Özet

Objective: This study investigates the predictive value of systemic inflammatory indices for repeat transuretral resection of bladder tumour (Re-TUR-BT) pathology in patients with high-risk non-muscle invasive bladder cancer (NMIBC). Materials and Methods: We conducted a retrospective analysis of 83 patients diagnosed with primary bladder tumors who underwent Re-TUR-BT based on initial pathology results from January 2014 to December 2023. Patients were categorized into two groups based on Re-TUR-BT pathology: Group 1 (non-malignant at Re-TUR-BT) and group 2 (malignant at Re-TUR-BT). We compared systemic inflammatory markers between these groups. Results: Of the 83 patients, 55 (82.5%) were in group 1 and 28 (17.5%) in group 2. Demographic characteristics showed no significant differences between the groups. However, upon comparison of operative and histopathological features, the incidence of T1 classification in first TUR-BT pathology, was significantly higher in group 2. Additionally, group 1 had a higher proportion of single tumors, whereas group 2 exhibited a greater incidence of two or more tumors, a difference that was statistically significant. Analysis of systemic inflammatory indices revealed no significant differences in the complete blood count results before the initial TUR-BT. However, both the systemic immune-inflammation index (SII) and neutrophil-to-lymphocyte ratio (NLR) showed significant differences before Re-TUR-BT. Conclusion: Our study indicates that SII and NLR calculated prior to Re-TUR-BT can predict malignant pathology persistence in high-risk NMIBC patients. These findings underscore the potential of systemic inflammatory indices as valuable biomarkers in clinical practice.